Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct‐acting antivirals? A prospective multicentre study
Alimentary Pharmacology & Therapeutics2017Vol. 46(7), pp. 688–695
Citations Over TimeTop 1% of 2017 papers
Giuseppe Cabibbo, Salvatore Petta, Vincenza Calvaruso, Irene Cacciola, M.R. Cannavò, Salvatore Madonia, Marco Distefano, Licia Larocca, Tullio Prestileo, Fabio Tinè, Gaetano Bertino, Lydia Giannitrapani, F. Benanti, Anna Licata, I. Scalisi, Giovanni Mazzola, F. Cartabellotta, Nicola Alessi, Marco Barbàra, M. Russello, G. Scifo, G. Squadrito, G. Raimondo, Antonio Craxı̀, V. Di Marco, Calogero Cammà, Rete Sicilia Selezione Terapia – HCV (RESIST‐HCV)
Abstract
Probability of HCC early recurrence in patients who had HCC previously cured remains high, despite HCV eradication by DAAs. Risk was comparable but not higher to that reported in literature in DAA-untreated patients. Previous HCC recurrence and tumour size can be used to stratify the risk of HCC early recurrence. Further studies are needed to assess impact of DAAs on late recurrence and mortality.
Related Papers
- → Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?(2018)22 cited
- Clinicopathologic features and risk factors for hepatocellular carcinoma: results from a single center in southern Turkey.(2003)
- Spontaneous rupture of hepatocellular carcinoma.(2002)
- Pathology of hepatocellular carcinoma(2006)
- The medical management of hepatocellular carcinoma (HCC) in Japan: a review with implications for HCC seen in the west.(1997)